The NCL was founded in 2004 in collaboration with NCI, FDA and NIST to provide free preclinical characterization of cancer nanomedicines to support their clinical translation. NCL also serves as an R&D partner for non-oncology nanomaterials, reformulation, and a variety of other applications. We have a multi-disciplinary staff of scientists with expertise in chemistry, pharmacology, toxicology, cancer biology, immunology, and formulation science. Since our founding, the NCL has characterized over 400 nanoparticles of all different types, collaborated with more than 100 universities and companies worldwide, and helped advance more than a dozen products into/through clinical trials.
